Thrombolysis and myocardial salvage: Results of clinical trials and the animal paradigm - paradoxic or predictable?

Circulation

Volumn 88, Issue 1, 1993, Pages 296-306

  Gersh, Bernard J ^a   Anderson, Jeffrey L ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; BLOOD CLOT LYSIS; CORONARY ARTERY BLOOD FLOW; ELECTROCARDIOGRAM; HEART EJECTION FRACTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMAL; DOGS; FIBRINOLYTIC AGENTS; HUMAN; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 0027322406     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.88.1.296     Document Type: Article

References (83)

1. Kennedy JW, Ritchie JL, Davis KB, Fritz JK. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med. 1983;309:1477-1482.
2. Ornato JP. Role of the emergency department in decreasing the time to thrombolytic therapy in acute myocardial infarction. Clin Cardiol. 1990;13(March suppl):V48-V52.
3. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 1992;339:753-770.
4. Reimer KA, Jennings RB. The "wavefront phenomenon" of myocardial ischemic cell death: II. transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest. 1979;40:633-644.
5. Jennings RB. Discussion: relationship of acute ischemia to functional defects and irreversibility. Circulation. 1976;53(suppl I):I-26-I-29.
6. 99mTc-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging for the assessment of myocardial area at risk and the effect of treatment in acute myocardial infarction. Circulation. 1989;80: 1277-1286.
7. Anderson JL. Overview of patency as an end point of thrombolytic therapy. Am J Cardiol. 1991;68:11E-16E.
8. Gruppo Italiano per lo Studio Della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-401.
9. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
10. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR, for the ASSET Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet. 1988;2:525-530.
11. AIMS Trial Study Group. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. Lancet. 1990;335:427-431.
12. Yusuf S, Sleight P, Held P, McMahon S. Routine medical management of acute myocardial infarction: lessons from overviews of recent randomized controlled trials. Circulation. 1990;82(suppl II): II-117-II-134.
13. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: should the paradigm be expanded? (editorial). Circulation. 1989; 79:441-444.
14. Califf RM, Topol EJ, Gersh BJ. From myocardial salvage to patient salvage in acute myocardial infarction: the role of reperfusion therapy. (editorial review) J Am Coll Cardiol. 1989;14: 1382-1388.
15. Anderson JL. Thrombolysis for acute myocardial infarction: making sense of the clinical trials data. J Intervent Cardiol. 1992;5:127-136.
16. Tiefenbrunn AJ, Sobel BE. Timing of coronary recanalization: paradigms, paradoxes, and pertinence. Circulation. 1992;85:2311-2315.
17. Roberts R, Kleiman N. The open artery: perspectives on coronary reperfusion in acute myocardial infarction. Hamilton, Ontario, Canada: Decker Periodicals, Inc, 1992:18-19.
18. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase; clinical findings through hospital discharge. Circulation. 1987;76:142-154.
19. The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet. 1990;336:71-75.
20. Verstraete M, Bernard R, Bory M, Brower RW, Collen D, de Bono DP, Erbel R, Huhmann W, Lennane RJ, Lubsen J, Mathey D, Meyer J, Michels HR, Rutsch W, Schartl M, Schmidt W, Uebis R, von Essen R. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet. 1985;1:842-847.
21. Pacouret G, Charbonnier B, Curien ND, Monassier JP, Cribier A, Materne P, Brochier ML, Letac R, Hanssen M, Sacrez A, Kulbertus H. Invasive reperfusion study: II. multicentre European randomized trial of anistreplase vs streptokinase in acute myocardial infarction. Eur Heart J. 1991;12:179-185.
22. Anderson JL, Sorensen SG, Moreno FL, Hackworthy RA, Browne KF, Dale HT, Leya F, Dangoisse V, Eckerson HW, Marder VJ, and the TEAM-2 Study Investigators. Multicenter patency trial of intravenous anistreplase compared with streptokinase in acute myocardial infarction. Circulation. 1991;83:126-140.
23. Anderson JL, Becker LW, Sorensen SG, Karagounis LA, Browne KF, Shah PK, Morris DC, Fintel DJ, Mueller HS, Ross AM, Hall SM, Askins JC, Doorey AJ, Grines CL, Moreno FL, Marder VJ, for the TEAM-3 Investigators. Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. J Am Coll Cardiol. 1992;20:753-766.
24. Topol EJ. Which thrombolytic agent should one choose? Prog Cardiovasc Dis. 1991;34:165-178.
25. Bates ER. Is survival in acute myocardial infarction related to thrombolytic efficacy or the open-artery hypothesis? A controversy to be investigated with GUSTO. Chest. 1992;101(suppl S):140S-150S.
26. Neuhaus K-L, Von Essen R, Tebbe U, Vogt A, Roth M, Riess M, Niederer W, Forycki F, Wirtzfeld A, Maeurer W, Limbourg P, Merx W, Haerten K. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC Patency Study (TAPS). J Am Coll Cardiol. 1992; 19:885-891.
27. Granger CB, Califf RM, Topol EJ. Review of thrombolytic therapy for acute myocardial infarction. Drugs. 1992;44:293-325.
28. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol. 1990;66:1412-1417.
29. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM, for the Heparin-Aspirin Reperfusion Trial (HART) Investigators. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1990;323:1433-1437.
30. White HD. GISSI-2 and the heparin controversy. Lancet. 1990;336: 297-298.
31. Arnout J, Simoons M, de Bono D, Rapold HJ, Collen D, Verstraete M. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). J Am Coll Cardiol. 1992;20:513-519.
32. O'Connor CM, Meese R, MacKrell J, Conne E, Burks J, Shadoff N, Hartman C, Roark S, Heard ME, Mittler B, Hanger K, Collins GJ, Lucas KD, Roberts G, Califf RM, for the DUCCS 1 Investigators. Reduced hemorrhagic complications following APSAC therapy in acute myocardial infarction by withholding heparin. (abstract) J Am Coll Cardiol. 1992;19:91A.
33. Hoffmann JJML, Bonnier JJRM, Melman PG, Bartholomeus I. Blood viscosity during thrombolytic therapy with anistreplase in acute myocardial infarction. Am J Cardiol. 1993;71:14-18.
34. Kitakaze M, Hori M, Takashima L, Sato H, Inoue M, Kamada T. Ischemic preconditioning increases adenosine release and 5′-nucleotidase activity during myocardial ischemia and reperfusion in dogs: implications for myocardial salvage. Circulation. 1993;87: 208-215.
35. Sinusas AJ, Trautman KA, Bergin JD, Watson DD, Ruiz M, Smith WH, Beller GA. Quantification of area at risk during coronary occlusion and degree of myocardial salvage after reperfusion with technetium-99m methoxyisobutyl isonitrile. Circulation. 1990;82: 1424-1437.
36. Christian TF, Gibbons RJ, Gersh BJ. Effect of infarct location on myocardial salvage assessed by technetium-99m isonitrile. J Am Coll Cardiol. 1991;17:1303-1308.
37. Sheehan FH, Mathey DG, Schofer J, Dodge HT, Bolson EL. Factors that determine recovery of left ventricular function after thrombolysis in patients with acute myocardial infarction. Circulation. 1985;71:1121-1128.
38. Ganz W, Shah PK. Temporal distribution of treatment to reperfusion times in patients with acute myocardial infarction: the effect of tissue plasminogen activator vs streptokinase. (abstract) J Am Coll Cardiol. 1992;19:361A.
39. The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med. 1983; 309:331-336.
40. Califf RM, Harrelson-Woodlief L, Topol EJ. Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. Circulation. 1990;82:1847-1853.
41. Van de Werf F. Discrepancies between the effects of coronary reperfusion on survival and left ventricular function. Lancet. 1989; 1:1367-1369.
42. Gibbons R, Holmes DR, Reeder GS, Bailey KR, Hopfenspringer M, Gersh BJ, for the Mayo Clinic CCU and Catheterization Lab Groups. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med. 1993 (in press)
43. Bergmann SR, Lerch RA, Fox KAA, Ludbrook PA, Welch MJ, Ter-Pogossian MM, Sobel BE. Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography. Am J Med. 1982;73:573-581.
44. Schaper W. Experimental Infarcts and the Microcirculation. In: Hearse DJ, Yellon DM, eds. Therapeutic Approaches to Myocardial Infarct Size Limitation. New York: Raven Press, 1984:79-90.
45. Spann JF, Sherry S. Coronary thrombolysis for evolving myocardial infarction. Drugs. 1984;28:465-483.
46. Timm TC, Ross R, McKendall GR, Braunwald E, Williams DO, and the TIMI Investigators. Left ventricular function and early cardiac events as a function of time to treatment with t-PA: a report from TIMI II. (abstract) Circulation. 1991;84(suppl II): II-230.
47. Held PH, Teo KK, Yusuf S. Effects of tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex on mortality in acute myocardial infarction. Circulation. 1990;82:1668-1674.
48. Weaver WO, Cerqueria M, Hallstrom AP, Litwin PE, Martin JS, Kudenchuk PJ, Eisenberg M, for the MITI Project Group. Early treatment with thrombolytic therapy: results from the Myocardial Infarction, Triage and Intervention Pre-Hospital Trial. JAMA. (in press).
49. The EMIP Group. Early pre-hospital intervention in patients with suspected acute myocardial infarction: results from a randomized controlled study. (submitted for publication).
50. National Heart Foundation of Australia Coronary Thrombolysis Group. Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction. Lancet. 1988;1:203-208.
51. Koren G, Weiss AT, Hasin Y, Appelbaum D, Welber S, Rozenman Y, Lotan C, Mosseri M, Sapoznikov D, Luria MH, Gotsman MS. Prevention of myocardial damage in acute myocardial ischemia by early treatment with intravenous streptokinase. N Engl J Med. 1985;313:1384-1389.
52. Mathey DG, Schofer J, Sheehan FH. Coronary thrombolysis with intravenous urokinase in patients with acute myocardial infarction. Am J Med. 1987;83(suppl 2A):26A-30A.
53. Christian TF, Schwartz RS, Gibbons RJ. Determinants of infarct size in reperfusion therapy for acute myocardial infarction. Circulation. 1992;86:81-90.
54. Hackett D, Davies G, Chierchia S, Maseri A. Intermittent coronary occlusion in acute myocardial infarction: value of combined thrombolytic and vasodilator therapy. N Engl J Med. 1987;317: 1055-1059.
55. Brown EJ Jr, Swinford RD, Gadde P, Lillis O. Acute effects of delayed reperfusion on myocardial infarct shape and left ventricular volume: a potential mechanism of additional benefits from thrombolytic therapy. J Am Coll Cardiol. 1991;17:1641-1650.
56. Hochman JS, Choo H. Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation. 1987;75:299-306.
57. Hale SL, Kloner RA. Left ventricular topographic alterations in the completely healed rat infarct caused by early and late coronary artery reperfusion. Am Heart J. 1988;116:1508-1513.
58. Jeremy RW, Hackworthy RA, Bautovich G, Hutton BF, Harris PJ. Infarct artery perfusion and changes in left ventricular volume in the month after acute myocardial infarction. J Am Coll Cardiol. 1987;9:989-995.
59. Touchstone DA, Beller GA, Nygaard TW, Tedesco C, Kaul S. Effects of successful intravenous reperfusion therapy on regional myocardial function and geometry in humans: a tomographic assessment using two-dimensional echocardiography. J Am Coll Cardiol. 1989;13:1506-1513.
60. Marino P, Zanolla L, Zardini P, on behalf of the Gruppo Italiano per lo Studio Della Streptochinasi nell'Infarto Miocardico (GISSI). Effect of streptokinase on left ventricular modeling and function after myocardial infarction: the GISSI (Gruppo Italiano per lo Studio Della Streptochinasi nell'Infarto Miocardico) trial. J Am Coll Cardiol 1989;14:1149-1158.
61. Hirayama A, Mishima M, Nanto S, Nishida K, Naito J, Matsuda T, Kodama K. Limitation of infarct expansion by late reperfusion independent of myocardial salvage in patients with acute myocardial infarction. (abstract) Circulation. 1991;84(suppl II):II-232.
62. Zaret BL, Wackers FJ, Terrin M, Ross R, Knatterud G, Braunwald E, and the TIMI Investigators. Does left ventricular ejection fraction following thrombolytic therapy have the same prognostic impact described in the prethrombolytic era? Results of the TIMI II Trial. (abstract) J Am Coll Cardiol. 1991;17:214A.
63. Sager PT, Perlmutter RA, Rosenfeld LE, McPherson CA, Wackers FJTh, Batsford WP. Electrophysiologic effects of thrombolytic therapy in patients with a transmural anterior myocardial infarction complicated by left ventricular aneurysm formation. J Am Coll Cardiol. 1988;12:19-24.
64. Bourke JP, Richards DAB, Ross DL, Wallace EM, McGuire MA, Uther JB. Routine programmed electrical stimulation in survivors of acute myocardial infarction for prediction of spontaneous ventricular tachyarrhythmias during follow-up: results, optimal stimulation protocol and cost-effective screening. J Am Coll Cardiol. 1991;18:780-788.
65. Gang ES, Lew AS, Hong M, Wang FZ, Siebert CA, Peter T. Decreased incidence of ventricular late potentials after successful thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1989;321:712-716.
66. Vatterott PJ, Hammill SC, Bailey KR, Wiltgen CM, Gersh BJ. Late potentials on signal-averaged electrocardiograms and patency of the infarct-related artery in survivors of acute myocardial infarction. J Am Coll Cardiol. 1991;17:330-337.
67. Moreno FLL, Karagounis L, Marshall H, Menlove RL, Ipsen S, Anderson JL. Thrombolysis-related early patency reduces ECG late potentials after acute myocardial infarction. Am Heart J. 1992; 124:557-564.
68. Calkins H, Maughan WL, Weisman HF, Sugiura S, Sagawa K, Levine JH. Effect of acute volume load on refractoriness and arrhythmia development in isolated, chronically infarcted canine hearts. Circulation. 1989;79:687-697.
69. Montalescot G, Faraggi M, Drobinski G, Messian O, Evans J, Grosgogeat Y, Thomas D. Myocardial viability in patients with Q wave myocardial infarction and no residual ischemia. Circulation. 1992;86:47-55.
70. Taylor GJ, Katholi RE, Womack K, Moses HW, Woods WT. Increased incidence of silent ischemia after acute myocardial infarction. JAMA. 1992;268:1448-1450.
71. Sabia PJ, Powers ER, Ragosta M, Sarembock IJ, Burwell LR, Kaul S. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med. 1992;327:1825-1831.
72. Sabia PJ, Powers ER, Jayaweera AR, Ragosta M, Kaul S. Functional significance of collateral blood flow in patients with recent acute myocardial infarction: a study using myocardial contrast echocardiography. Circulation. 1992;85:2080-2089.
73. Dzavik V, Beanlands DS, Davies RF, Ruddy TD, Marquis J-F. Beneficial effect of successful late PTCA on LV ejection fraction in patients with a recent infarct related coronary artery occlusion. (abstract) J Am Coll Cardiol. 1992;19:229A.
74. Weaver WD, Eisenberg MS, Martin JS, Litwin PE, Shaeffer SM, Ho MT, Kudenchuk P, Hallstrom AP, Cerqueira MD, Copass MK, Kennedy JW, Cobb LA, Ritchie J. Myocardial infarction triage and intervention project-phase I: patient characteristics and feasibility of prehospital initiation of thrombolytic therapy. J Am Coll Cardiol. 1990;15:925-931.
75. Karagounis L, Ipsen SK, Jessop MR, Gilmore KM, Valenti DA, Clawson JJ, Teichman S, Anderson JL. Impact of field-transmitted electrocardiography on time to in-hospital thrombolytic therapy in acute myocardial infarction. Am J Cardiol. 1990;66:786-791.
76. Kereiakes DJ, Weaver WD, Anderson JL, Feldman T, Gibler B, Aufderheide T, Williams DO, Martin LH, Anderson LC, Martin JS, McKendall G, Sherrid M, Greenberg H, Teichman SL. Time delays in the diagnosis and treatment of acute myocardial infarction: a tale of eight cities. Report from the Pre-Hospital Study Group and the Cincinnati Heart Project. Am Heart J. 1990;120: 773-779.
77. Anderson JL, Rothbard RL, Hackworthy RA, Sorensen SG, Fitzpatrick PG, Dahl CF, Hagan AD, Browne KF, Symkoviak GP, Menlove RL, Barry WH, Eckerson HW, Marder VJ, for the APSAC Multicenter Investigators. Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase. J Am Coll Cardiol. 1988;11: 1153-1163.
78. Anderson JL, Moreno FL. Thrombolytic therapy and alphabet soup: a short lexicon. J Intervent Cardiol. 1991;4:221-230.
79. ACC/AHA Task Force Report. Guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (subcommittee to develop guidelines for the early management of patients with acute myocardial infarction). J Am Coll Cardiol. 1990;16:249-292.
80. Sharkey SW, Brunette DD, Ruiz E, Hession WT, Wysham DG, Goldenberg IF, Hodges M. An analysis of time delays preceding thrombolysis for acute myocardial infarction. JAMA. 1989;262: 3171-3174.
81. Gonzalez ER, Ornato JP, Jones LA, Bleecker GC, Strauss MJ, and the Virginia Thrombolytic Study Group. Prospective multicenter assessment of critical factors delaying hospital thrombolytic therapy. (abstract) J Am Coll Cardiol. 1991;17:247A.
82. Leizorovicz A, Boissel J-P, Robert F. Coronary reperfusion rates in acute myocardial infarction patients after thrombolytic treatment with anistreplase: correlation with the delay from onset of symptoms to treatment: a review of 424 case records of patients admitted to coronary reperfusion studies with anistreplase. J Cardiovasc Pharmacol. 1992;19:34-39.
83. Arnold AER, Ferdinand RF, Soward AL, Schmidt WG, Lubsen J. Thrombolysis in Suspected Acute Myocardial Infarction: A Summary. Frankfurt, Germany: Unirsersimed Verlag GmbH, 1990.